Reports Q4 revenue $6.1M, consensus $7.09M. In 2018, we committed to focus on our two lead programs, ResVax(TM) and Nanoflu(TM), and reflecting on last year’s activities, I am proud to say we have achieved significant results for both,” said Stanley C. Erck, President and CEO of Novavax, Inc. “Although we were disappointed to miss the primary endpoint of our Prepare trial, ResVax is the first RSV vaccine to demonstrate efficacy for the prevention of RSV disease in a Phase 3 clinical trial. In addition, the successful Phase 2 results for our NanoFlu vaccine provide an opportunity to now confirm with the FDA the use of accelerated approval for licensure. We are now prepared to make meaningful advances on these programs during 2019.”
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.